489 related articles for article (PubMed ID: 18835576)
1. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
Lahiri A; Das P; Chakravortty D
Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
[TBL] [Abstract][Full Text] [Related]
2. Drugs targeting Toll-like receptors.
Krishnan J; Lee G; Choi S
Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
[TBL] [Abstract][Full Text] [Related]
3. Toll or toll-free adjuvant path toward the optimal vaccine development.
Ishii KJ; Akira S
J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.
Ketloy C; Engering A; Srichairatanakul U; Limsalakpetch A; Yongvanitchit K; Pichyangkul S; Ruxrungtham K
Vet Immunol Immunopathol; 2008 Sep; 125(1-2):18-30. PubMed ID: 18571243
[TBL] [Abstract][Full Text] [Related]
5. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors' two-edged sword: when immunity meets apoptosis.
Salaun B; Romero P; Lebecque S
Eur J Immunol; 2007 Dec; 37(12):3311-8. PubMed ID: 18034428
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor ligands energize peptide vaccines through multiple paths.
Celis E
Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
[TBL] [Abstract][Full Text] [Related]
8. The future of toll-like receptor therapeutics.
Parkinson T
Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
[TBL] [Abstract][Full Text] [Related]
9. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptors and innate immunity.
Kumar H; Kawai T; Akira S
Biochem Biophys Res Commun; 2009 Oct; 388(4):621-5. PubMed ID: 19686699
[TBL] [Abstract][Full Text] [Related]
11. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention].
Kabelitz D
Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of the innate immune system in domestic animals.
Coffey TJ; Werling D
Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
[TBL] [Abstract][Full Text] [Related]
13. Modulating vaccine responses with dendritic cells and Toll-like receptors.
Pulendran B
Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
[TBL] [Abstract][Full Text] [Related]
14. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
[TBL] [Abstract][Full Text] [Related]
15. T cell-dependent and -independent IgA responses: role of TLR signalling.
Bessa J; Bachmann MF
Immunol Invest; 2010; 39(4-5):407-28. PubMed ID: 20450285
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic and therapeutic implications of toll-like receptor ligands.
Hedayat M; Takeda K; Rezaei N
Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
[TBL] [Abstract][Full Text] [Related]
17. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
Makkouk A; Abdelnoor AM
Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
[TBL] [Abstract][Full Text] [Related]
18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
19. [Toll-like receptors].
Essakalli M; Atouf O; Bennani N; Benseffaj N; Ouadghiri S; Brick C
Pathol Biol (Paris); 2009 Jul; 57(5):430-8. PubMed ID: 18513891
[TBL] [Abstract][Full Text] [Related]
20. Endogenous TLR ligands and autoimmunity.
Wagner H
Adv Immunol; 2006; 91():159-73. PubMed ID: 16938540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]